Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.51 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL227115 | 0.90 | ESR1 (0.73) | ESR1CYP19A1ESR2POLBABCB1 | |
| SCHEMBL4736569 | 0.88 | ESR1 (0.82) | ESR1CYP19A1ESR2POLBCALM1 | |
| SCHEMBL8686118 | 0.87 | TDP1 (0.56) | ESR1CYP19A1ESR2POLBL3MBTL1 | |
| SCHEMBL30419864 | 0.85 | ALOX5 (0.66) | ESR1CYP19A1ESR2POLBMAOB | |
| SCHEMBL6061390 | 0.83 | LTA4H (0.50) | ESR1CYP19A1ESR2POLBMAOB | |
| SCHEMBL1847390 | 0.83 | ESR1 (0.69) | ESR1CYP19A1ESR2POLBCALM1 | |
| SCHEMBL29492427 | 0.83 | ESR1 (0.69) | ESR1CYP19A1ESR2POLBCALM1 | |
| SCHEMBL29492460 | 0.83 | GABRA1 (0.59) | ESR1CYP19A1ESR2POLBABCB1 | |
| SCHEMBL21830506 | 0.83 | GABRA1 (0.59) | ESR1CYP19A1ESR2POLBABCB1 | |
| SCHEMBL29350108 | 0.82 | TDP1 (0.61) | L3MBTL1TDP1ABCB1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | SCHERING AG (DE) | 2011-01-13 | — | — | US | disclosed |
| EP-1280776-B1 | SUBSTITUTED BENZOIC ACID AMIDES AND USE THEREOF FOR THE INHIBITION OF ANGIOGENESIS | BAYER SCHERING PHARMA AG (DE) | 2009-10-21 | — | — | EP | disclosed |
| EP-1280776-A1 | SUBSTITUTED BENZOIC ACID AMIDES AND USE THEREOF FOR THE INHIBITION OF ANGIOGENESIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2001081311-A1 | SUBSTITUTED BENZOIC ACID AMIDES AND USE THEREOF FOR THE INHIBITION OF ANGIOGENESIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-11-01 | — | — | WO | disclosed |
| US-5843983-A | Diphenylethane compounds containing a saturated heterocyclic group, their preparation, and their therapeutic use | SANKYO COMPANY, LIMITED (JP) | 1998-12-01 | — | — | US | disclosed |
| EP-0790235-A1 | Diaryl alkane derivatives containing an alicyclic group, their preparation and their therapeutic and prophylactic uses | SANKYO COMPANY LIMITED (JP) | 1997-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009447-A1 | Substituted Benzoic Acid Amides and Use thereof for the Inhibition of Angiogenesis | VEGFA, EGLN2, HIF1AN | ESR1 526/4885CYP19A1 51/4885ESR2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.